Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Castle Biosciences Inc.
< Previous
1
2
Next >
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
January 09, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
January 07, 2024
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
December 01, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
November 14, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
November 13, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at Upcoming Investor Conferences
November 08, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
November 03, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy
November 02, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports Third Quarter 2023 Results
November 02, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting
October 24, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2
October 19, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
October 18, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma
October 05, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Presents New Data at ASTRO 2023 Highlighting Risk-Stratification Performance of DecisionDx®-SCC in Patients with Cutaneous Squamous Cell Carcinoma Eligible for Adjuvant Radiation Therapy
October 03, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
October 02, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry
September 19, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
September 14, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
September 12, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression
September 09, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023
September 06, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Participate in Upcoming Investor Conferences
September 05, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
August 07, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports Second Quarter 2023 Results
August 02, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 01, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
July 19, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year
July 17, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer
July 07, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology
June 30, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2023
From
Castle Biosciences Inc.
Via
Business Wire
Tickers
CSTL
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.